Company Location Date Amt. (M) Details

Abiant Inc. Chicago 10/1 $0.6 Abiant raised $600,000 in a financing led by Heartland Angels and including the Kettering Medical Center and other participants
Acceleron Pharma Inc. Cambridge, Mass. 10/30 $31 Acceleron raised $31M from a Series C financing led by Bessemer Venture Partners; other investors were MPM BioEquities and QVT Financial, as well as Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock
Allozyne Inc. Seattle 10/26 $30 Allozyne raised $30M in a Series B round led by MPM Capital, with participation from OVP Venture Partners, Amgen Ventures, ARCH Venture Partners and Alexandria Real Estate Equities Inc.
APT Pharmaceuticals Inc. Burlingame, Calif. 10/4 $22 APT raised $22M in a Series A-2 round led by Versant Ventures and Great Point Partners and included Vivo Ventures and Charter Life Sciences
Bellicum Pharmaceuticals Inc. Houston 10/10 $3.75 Bellicum was awarded $1.45M by the Texas Emerging Technology Fund and received seed financing of $2.3M
Cumbre Inc. Dallas 10/9 ND Cumbre's existing investors provided an undisclosed amount of new capital
DeltaDOT Ltd. London 10/1 L6 ($12.1) DeltaDOT raised $6.05M in the fourth tranche of a private financing round, bringing the total amount raised to L6M ($12.1M)
Direvo Biotech AG Cologne, Germany 10/18 E12 ($16.8) Direvo raised $16.8M in a Series C round led by Bankhause Wolbern and TVM Capital; other investors were Danisco Venture A/S, S-Equity Partner, Mulligan BioCapital and funds managed by Signet Healthcare Partners, as well as private investors
Genetic Immunity LLC New York 10/10 $2 Genetic Immunity completed a $2M bridge financing
HistoRx Inc. New Haven, Conn. 10/24 $6 HistoRx raised $6M in a Series B financing led by Brook Venture Partners; it included participation by Navigator Technology Ventures and Roche Venture Fund, Commons Capital and Maven Capital
Hyperion Therapeutics Inc. South San Francisco 10/4 $15 Hyperion closed up to $15M in debt financing from Comerica Bank and Life Sciences Capital
Ikonisys Inc. New Haven, Conn. 10/17 $30 Ikonisys secured $30M in a Series E financing; investors were Goldman, Sachs & Co., Trevi Health Ventures, Palisade Capital, Everfin, Lakeview Capital Management, New Science Ventures, Promark Holdings SA, Saint Simeon - e Investimentos Lda and WHI Group
ImmuneWorks LLC Indianapolis 10/30 $0.3 ImmuneWorks raised $300,000 from the Indiana Seed Fund I managed by BioCrossroads
Linkage Biosciences Inc. San Francisco 10/16 $1 Linkage raised $1M in seed financing led by Greenhouse Capital Partners LP
Mendel Biotechnology Inc. Hayward, Calif. 10/15 ND Mendel completed a financing round in which ZBI Ventures, Capricorn Investment Group and CFM became new investors
Metastatix Inc. Atlanta 10/9 $35 Metastatix raised $35M in a Series B round led by Frazier Healthcare Ventures, and included participation by H.I.G. Ventures, The Aurora Funds, CM Capital, SR One, MedImmune Ventures, Georgia Venture Partners, Centrosome Ventures and the State of Georgia
Optherion Inc. New Haven, Conn. 10/9 $37 Optherion raised $37M in a Series A round led by Quaker BioVentures and Domain Associates LLC; other investors were Johnson & Johnson Development Corp., Purdue Pharmaceutical Products LP, Pappas Ventures, Biogen Idec New Ventures and GE Healthcare Financial Services
Oxford Immunotec Oxford, UK 10/29 $40 Oxford closed a $40M round co-led by Clarus Ventures and Wellington Partners; other investors were National Technology Enterprises Co., the Prelude Trust, Quester and Dow Chemical Co.
Paratek Pharmaceuticals Inc. Boston 10/25 $22 Paratek raised $22M in the first tranche of its Series H round, with the remaining $18M expected in early 2008; Aisling Capital led the round and was joined by D.E. Shaw, Boston Life Science Venture Corp., Nomura Phase4 Ventures, Novartis BioVentures, BioFund Ventures, HBM BioVentures, Lombard Odier Darier Hentsch, BioVeda Fund and Hercules Technology Growth
Phase Bioscience Inc. Durham, N.C. 10/24 $6.6 Phase raised an additional $5.4M in Series B financing, bringing the total round to $6.6M; Fletcher Spaght Ventures co-led the round with Johnson & Johnson Development Corp.; Hatteras Venture Partners also invested
Regenetech Inc. Houston 10/30 $2.5 Regenetech raised $2.5M in private equity financing from individual investors coordinated by Outrider Investors LLC and brokerage firm Royal Securities Co.
Relypsa Inc. Santa Clara, Calif. 10/30 $33 Relypsa raised $33M in a Series A round led by 5AM Ventures and New Leaf Venture Partners; other investors were the Sprout Group, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners
Rules-Based Medicine Inc. Austin, Texas 10/15 $25 Rules-Based raised $25M in a Series A financing; Equity Group Investments LLC led the round and was joined by Cross Creek Capital and Stephens Capital Partners
Tego Biosciences Corp. Pasadena, Calif. 10/25 $2.4 Tego raised $2.4M through Arrowhead Research Corp. (ARWR), its parent company
Tengion Inc. East Norriton, Pa. 10/15 $33 Tengion raised $33M in a Series C round that includes investments from Deerfield Partners, Bain Capital LLC, HealthCap, Quaker BioVentures, Oak Investment Partners, L Capital Partners, Johnson & Johnson Development Corp., Horizon Technology Finance LLC and Oxford Finance Corp.
WellGen Inc. North Brunswick, N.J. 10/29 $9.5 WellGen completed its Series C round worth $9.5M with new and existing shareholders
Xcellerex Inc. Marlborough, Mass. 10/11 $31 Xcellerex raised $31M in a Series C financing led by VantagePoint Venture Partners; Kleiner Parkins Caufield and Byers, and SCG Investments also participated (10/11)
Xencor Inc. Monrovia, Calif. 10/25 $15 Xencor raised an additional $15M in its Series E financing, bringing the total to $60M; investors were Oxford Bioscience Partners, Merlin Nexus and Novo Nordisk AS


Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International. ND = Not disclosed.